Sanofi (SAN) ESG Investor Roadshow conference summary
Event summary combining transcript, slides, and related documents.
ESG Investor Roadshow conference summary
3 Feb, 2026Opening and strategic context
Event focused on ESG strategy, highlighting integration of sustainability into business growth and value creation for society, patients, and the environment.
Agenda included deep dives on access to healthcare, environmental impact, healthcare system resilience, and inclusion.
Emphasis on business representatives sharing sustainability execution and alignment with the Play to Win strategy.
Sustainability strategy and AIR program
Refreshed AIR strategy focuses on Access, Impact, and Resilience, validated by executive committee and board, and fully integrated into business planning.
Transitioning from flagship commitments to a holistic, integrated approach involving all business units and functions.
Sustainability fundamentals are being embedded across the value chain to drive responsible business practices.
Ongoing evaluation and adjustment of goals, metrics, and targets in response to evolving standards and risks.
Access to healthcare initiatives
Programs target vulnerable populations in international markets and LMICs, focusing on respiratory and diabetes care, school-based education, and mobile health units.
Over 931,000 patients reached with NCD treatments in 33 countries; goal to reach 1.5 million by 2026.
Global Health Unit operates as a not-for-profit, reaching nearly 1 million patients in 40 countries, with investments in healthcare startups impacting 10 million patients.
Business models range from full-value to inclusive, with partnerships to elevate care standards.
Latest events from Sanofi
- Strong 2024 growth, innovation, and all resolutions passed with high approval.SAN
AGM 20253 Feb 2026 - Double-digit 2025 sales and EPS growth, strong launches, and high single-digit 2026 outlook.SAN
Q4 20253 Feb 2026 - Q2 2024 sales up 10.2% at CER, EPS guidance raised, and pipeline momentum continues.SAN
Q2 20242 Feb 2026 - Strong pipeline, disciplined execution, and key launches drive growth and value creation.SAN
Goldman Sachs 45th Annual Global Healthcare Conference2 Feb 2026 - Q2 sales up 10.1%, led by Dupixent and vaccines; 2025 outlook upgraded on strong pipeline.SAN
Q2 202522 Jan 2026 - Tolebrutinib delayed disability progression in MS, with manageable liver safety and filings set for 2024.SAN
Status Update20 Jan 2026 - Q3 sales up 16% at CER, 2024 EPS guidance raised, and Opella divestment to refocus on biopharma.SAN
Q3 202418 Jan 2026 - Double-digit growth targeted through 2030, fueled by innovation and robust new launches.SAN
44th Annual J.P. Morgan Healthcare Conference16 Jan 2026 - Double-digit growth, blockbuster launches, and a robust pipeline drive strong 2025 outlook.SAN
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026